Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...
Several high-profile companies are looking to leverage artificial intelligence (AI) capabilities to disrupt the healthcare sector. That's because drug development is risky, expensive, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results